Vaccines for melanoma and renal cell carcinoma

Seminars in Oncology

Volumn 39, Issue 3, 2012, Pages 263-275

  Kaufman, Howard L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETA CATENIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; EPHRIN RECEPTOR A2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; M VAX; MELAN A; MELANOMA ANTIGEN 3; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; PLACEBO; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; SIPULEUCEL T; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIMOGENE ALIPLASMID; VITESPEN;

ADVANCED CANCER; ARTICLE; AUTOIMMUNE THYROIDITIS; BREAST CANCER; CANCER IMMUNIZATION; CANCER PATIENT; COLORECTAL CANCER; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG MEGADOSE; ENDOGENOUS RETROVIRUS; ERYTHEMA; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LOW DRUG DOSE; MELANOMA; METASTATIC MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MELANOMA;

EID: 84861133191     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.02.011     Document Type: Article

References (88)

1. American Cancer Society: Facts and Figures, 2012 http://www.cancer.org/ acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
2. C. Garbe, T.K. Eigentler, U. Keliholz, A. Hauschild, J.M. Kirkwood Systematic review of medical treatment in melanoma: current status and future prospects Oncologist 16 2011 5 24
3. J.F. Thompson, H.M. Shaw Sentinel node mapping for melanoma: results of trials and current applications Surg Oncol Clin N Am 16 2007 35 54 (Pubitemid 46335780)
4. S. Mocellin, S. Pasquali, C.R. Rossi Interferon-alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 102 2010 493 501
5. K. Wheatley, N. Ives, B. Hancock Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomized trials Cancer Treat Rev 29 2003 241 252 (Pubitemid 37069655)
6. C.M. Balch, J.E. Gershenwald, S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
7. G.K. Antony, A.Z. Dudek Interleukin-2 in cancer therapy Curr Med Chem 17 2010 3297 3302
8. S.F. Hodi, S.J. O'Day, D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2011 711 723
9. P.B. Chapman, A. Hauschild, C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
10. M. Itsumi, K. Tatsugami Immunotherapy for renal cell carcinoma Clin Dev Immunol 2010 2010 284581
11. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011
12. M.J. Leveridge, M.A. Jewett Recent developments in kidney cancer Can Urol Assoc J 5 2011 195 203
13. D.F. McDermott, M.B. Atkins Immunotherapy of metastatic renal cell carcinoma 2008 Cancer J 14 2008 320 324
14. A.M. Molina, R.J. Motzer Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow Oncologist 16 2011 45 50
15. D.A. Oble, R. Loewe, P. Yu, M.C. Mihm Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma Cancer Immun 9 2009 3
16. S. Kim-Schulze, B. Taback, H.L. Kaufman Cytokine therapy for cancer Surg Oncol Clin N Am 16 2007 793 818 (Pubitemid 350110404)
17. R. Childs, A. Chernoff, N. Contentin Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med 343 2000 750 758
18. S.A. Rosenberg, M.E. Dudley Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol 21 2009 233 240
19. Y. Kawakami, P.F. Robbins, R.F. Wang, M. Parkhurst, X. Kang, S.A. Rosenberg The use of melanosomal proteins in the immunotherapy of melanoma J Immunother 21 1998 237 246 (Pubitemid 28328403)
20. P.G. Coulie, V. Brichard, A. Van Pel A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas J Exp Med 180 1994 35 42 (Pubitemid 24181053)
21. K.R. Lindsey, L. Gritz, R. Sherry Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma Clin Cancer Res 15 2006 2526 2537
22. A. Boni, P. Muranski, L. Cassard Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers Blood 112 2008 4746 4754
23. R.F. Wang, S.L. Johnston, S. Southwood, A. Sette, S.A. Rosenberg Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33 J Immunol 160 1998 890 897 (Pubitemid 28049332)
24. E. Elkord, A. Shablak, P.L. Stern, R.E. Hawkins 5T4 as a target for immunotherapy in renal cell carcinoma Exp Rev Anticancer Ther 9 2009 1705 1709
25. V. Askoxylakis, R. Garcia-Boy, S. Rana A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phase display technology PLoS One 5 2010 e15962
26. N. Peled, A.B. Oton, F.R. Hirsch, P. Bunn MAGE A3 antigen-specific cancer immunotherapeutic Immunotherapy 1 2009 19 25
27. S. Gnjatic, H. Nishikawa, A.A. Jungbluth NY-ESO-1: review of an immunogenic tumor antigen Adv Cancer Res 95 2006 1 30 (Pubitemid 44088423)
28. M.J. Scanlan, A.O. Gure, A.A. Jungbluth, L. Old, Y.T. Chen Cancer/testis antigens: an expanding family of targets for cancer immunotherapy Immunol Rev 188 2002 22 32 (Pubitemid 35398862)
29. P.F. Robbins, M. El-Gamil, Y.F. Li A mutated beta catenin gene encodes a melanoma-specific antigen recognized by tumor-infiltrating lymphocytes J Exp Med 83 1996 1185 1192
30. M. Tandon, S.V. Vemula, S.K. Mittal Emerging strategies for EPhA2 receptor targeting for cancer therapeutics Expert Opin Ther Targets 15 2011 31 51
31. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma Cancer Res 63 2003 4481 4489 (Pubitemid 36951020)
32. Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 2007 1915 1927
33. K. Buscher, U. Trefzer, M. Hofmann, W. Sterry, R. Kurth, J. Denner Expression of human endogenous retrovirus K in melanoma and melanoma cell lines Cancer Res 65 2005 4172 4180 (Pubitemid 40775655)
34. F. Schiavetti, J. Thonnard, D. Colau, T. Boon, P.G. Coulie A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes Cancer Res 62 2002 5510 5516
35. O.J. Finn Cancer immunology N Engl J Med 358 2008 2704 2715
36. R.M. Steinman, J. Banchereau Taking dendritic cells into medicine Nature 449 2007 419 426 (Pubitemid 47509552)
37. A.B. Frey, N. Monu Signaling defects in anti-tumor T cells Immunol Rev 222 2008 192 205 (Pubitemid 351430368)
38. + T cells in anti-tumor immune responses Immunol Rev 222 2008 129 144 (Pubitemid 351430378)
39. E. Elkord, E.M. Alcantar-Orozco, S.J. Dovedi, D.Q. Tran, R.E. Hawkins, D.E. Gilham T regulatory cells in cancer: recent advances and therapeutic potential Expert Opin Biol Ther 10 2010 1573 1586
40. F. Zhao, J. Dou, X.F. He Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model Vaccine 28 2010 2846 2852
41. P.J. Wysocki, U. Kazimierczak, W. Suchorska, M. Koltarski, J.M. Malicki, A. Mackiewicz Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interluekin-6 is an effective therapy in mice bearing orthotopic renal cell cancer Cancer Gene Ther 17 2010 465 475
42. C.L. Slingluff, G.R. Petroni, G.V. Yamshchikov Clinical and immunologic results of a randomized phase II trial of vaccination using four peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells J Clin Oncol 21 2003 4016 4026 (Pubitemid 46606217)
43. + T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial Clin Cancer Res 15 2009 7036 7044
44. J.M. Kirkwood, S. Lee, S.J. Moschos Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-macrophage colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern cooperative oncology group phase II trial E1696 Cancer Res 15 2009 1443 1451
45. D.H. Lawson, S.J. Lee, A.A. Tarhini E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma J Clin Oncol 28 2010 15s [abstract 8504]
46. D.J. Schwartzentruber, D.H. Lawson, J.M. Richards gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2011 2119 2127
47. T.M. Clay, M.C. Custer, M.D. McKee Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue J Immunol 162 1999 1749 1755 (Pubitemid 29307054)
48. J.A. Sosman, C. Carillo, W.J. Urba Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma J Clin Oncol 26 2008 2292 2298
49. M.B. Atkins, M.T. Lotze, J.P. Dutcher High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116 (Pubitemid 29318842)
50. P. Srivastava Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses Annu Rev Immunol 20 2002 395 425 (Pubitemid 34293430)
51. C. Wood, P. Srivastava, R. Bukowski An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomized phase III trial Lancet 372 2008 145 154
52. A.A. Jungbluth, W.A. Silva, K. Iversen Expression of cancer-testis (CT) antigens in placenta Cancer Immun 7 2007 15 22
53. A.O. Gure, R. Chua, B. Williamson Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer Clin Cancer Res 11 2005 8055 8062 (Pubitemid 41698748)
54. + T cell responses to MAGE-3 protein in lung cancer patients J Immunol 172 2004 3289 3296 (Pubitemid 38263721)
55. J. Vansteenkiste, M. Zielinski, A. Linder Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) J Clin Oncol 25 2007 [abstract 7554]
56. W.H. Kruit, H.H. van Ojik, V.G. Brichard Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma Int J Cancer 117 2005 596 604 (Pubitemid 41504547)
57. A.Y. Bedikan, J. Richards, D. Kharkevitch, M.B. Atkins, E. Whitman, R. Gonzalez A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma Melanoma Res 20 2010 218 226
58. R. Chowdhery, R. Gonzalez Immunologic therapy targeting metastatic melanoma: allovectin-7 Immunotherapy 3 2011 17 21
59. P.M. Arlen, H.L. Kaufman, R.S. DiPaola Pox viral vaccine approaches Semin Oncol 32 2005 549 555 (Pubitemid 41772682)
60. D.H. Kim, S.H. Thorne Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer Nature Rev Cancer 9 2009 64 71
61. D.L. Lodmell, L.C. Ewalt Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines Vaccine 22 2000 2394 2398 (Pubitemid 30156810)
62. R.W. Griffiths, D.E. Gilham, A. Dangoor Expression of the 5T4 oncofetal antigen in renal cell carcinoma: a potential target for T-cell based immunotherapy Br J Cancer 93 2005 670 677 (Pubitemid 41486458)
63. R.E. Hawkins, C. McDermott, A. Shablak Vaccination of patients with metastatic renal cell cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha J Immunother 32 2009 424 429
64. R.J. Amato, W. Shingler, S. Naylor Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin-2: a phase II trial Clin Cancer Res 14 2008 7504 7510
65. H.L. Kaufman, B. Taback, W. Sherman Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma J Transl Med 7 2009 2
66. R.J. Amato, R.E. Hawkins, H.L. Kaufman Vaccination of metastatic renal cell cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study Clin Cancer Res 16 2010 5539 5547
67. R. Harrop, W.H. Shingler, M. McDonald MVA-5T4-induced immune responses are and early marker of efficacy in renal cancer patients Cancer Immunol Immunother 60 2011 829 837
68. B.L. Liu, M. Robinson, Z.Q. Han ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties Gene Ther 10 2003 292 303 (Pubitemid 36305598)
69. J.C. Hu, R.S. Coffin, C.J. Davis A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor Clin Cancer Res 12 2006 6737 6747 (Pubitemid 44876843)
70. GM-CSF) in patients with unresectable metastatic melanoma (stages IIIc/IV) J Clin Oncol 27 2009 5763 5771
71. H.L. Kaufman, D.W. Kim, G. DeRaffele, J. Mitcham, R. Coffin, S. Kim-Schulze Local immunity induced by intralesional vaccination with an oncolytic herpesvirus encoding GM-CSF in patients with stage IIIc and IV melanoma Ann Surg Oncol 17 2010 718 730
72. H.L. Kaufman, S. Bines OPTIM trial: a phase III trial of an oncolytic virus encoding GM-CSF for unresectable stage III or IV melanoma Future Oncol 6 2010 941 949
73. P.W. Kantoff, C.F. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
74. D. Jocham, A. Richter, L. Hoffmann Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trial Lancet 363 2004 594 599 (Pubitemid 38264176)
75. E.C. Hsueh, R. Essner, L.J. Foshag Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine J Clin Oncol 20 2002 4549 4554 (Pubitemid 35402957)
76. D.L. Morton, N. Mozillo, J.F. Thompson An international, randomized phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites J Clin Oncol 25 18 suppl 2001 [abstract 1078]
77. G.J. Tsiolias, R.K. Gupta, G. Tsiman Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma Ann Surg Oncol 8 2001 198 203 (Pubitemid 32294798)
78. D. Berd M-Vax: an autologous, hapten-modified vaccine for human cancer Expert Opin Biol Ther 2 2002 335 342 (Pubitemid 34464814)
79. D. Berd, T. Sato, H. Cohn, H.C. Maguire, M.J. Mastrangelo Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases Int J Cancer 94 2001 531 539
80. US National Institutes of Health M-Vax + low-dose interleukin-2 versus placebo vaccine in metastatic melanoma in patients with stage IV melanoma http://clinicaltrials.gov/ct2/show/NCT000003674 Accessed June 11, 2011
81. A.M.M. Eggermont Vaccine trials in melanoma - time for reflection Nature Rev Clin Oncol 6 2009 256 258
82. T.J. Stewart, M.J. Smyth Improving cancer immunotherapy by targeting tumor-induced immune suppression Cancer Metast Rev 30 2011 125 140
83. E.M. Shevach The resurrection of T cell-mediated suppression J Immunol 186 2011 3805 3807
84. + regulatory T cells in patients treated with high-dose interleukin-2 (IL-2) for metastatic melanoma and renal cell carcinoma J Clin Oncol 24 2006 1169 1177 (Pubitemid 46638815)
85. S. Mocellin, E. Wang, F.M. Marincola Cytokines and immune response in the tumor microenvironment J Immunother 24 2001 392 407 (Pubitemid 33029909)
86. T.F. Gajewski Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment Clin Cancer Res 13 2007 5256 5261 (Pubitemid 47510348)
87. J.J. Lindenberg, C.M. Fehres, H. van Cruijsen, D. Oosterhoff, T.D. de Gruijl Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity Immunotherapy 3 2011 77 96
88. M.A. Rasku, A.L. Chen, S. Telang Transient T cell depletion causes regression of melanoma metastases J Transl Med 6 2008 12